Advanced Cancer Topics Journal Review 4/16/2009 AD.

Slides:

Advertisements

Similar presentations

Shyamala Maherswaran, Ph.D. et al. Sarah Gomez and Rachael Holmes Detection of Mutations in EGFR in Circulating Lung-Cancer Cells.

Advertisements

Clinical developmentDiscovery Typical development timeline Typically – 8 yearsTypically 7 years.

Controlling a Killer Malfunction By: Brady Sebo, Tom Fish, Addela Marzofka, and Colton Cummings

THE GENETIC OF CANCER Increased mitosisTumor formation Tumor suppression gene Hyperactive growth TranslocationPoint mutationAmplification Normal growth.

Tumor Therapy with Monoclonal Antibodies

KRAS testing in colorectal cancer: an overview. 2 What is KRAS? KRAS is a gene that encodes one of the proteins in the epidermal growth factor receptor.

Detection of Mutations in EGFR in Circulating Lung-Cancer Cells Colin Reisterer and Nick Swenson S. Maheswaran et al. The New England Journal of Medicine.

Jennie Bell CMGS/ACC Spring meeting 14 th April 2010.

In vivo animal model studies in biological science 1.Cancer 2. Neuroscience 1.Cancer research 2. Neuroscience.

Epidermal Growth Factor Receptors (ErbB-1) and it’s role in Cancer By Jeron Fleming Photo retrieved from

Manifestation of Novel Social Challenges of the European Union in the Teaching Material of Medical Biotechnology Master’s Programmes at the University.

New Developments in Cancer Treatment Dulcinea Quintana, MD.

Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR-TKI) in Non-Small Cell Lung Cancer (NSCLC) Victor.

Computational biology of cancer cell pathways Modelling of cancer cell function and response to therapy.

Dr Francis Daniel, MB. ChB, FFR-RCSI, FRCR. Consultant in Clinical Oncology

© 2005 Prentice Hall Inc. / A Pearson Education Company / Upper Saddle River, New Jersey Lung Cancer and Gefitinib  Lung cancer statistics in the.

EXPRESSION OF HER-2 CORRELATED PROTEINS IN ILEAL CARCINOIDS Azzoni C., Giordano G., Bottarelli L., Tamburini E., D’Adda T., Pizzi S., Rindi G., Bordi C.

Tyrosine Kinases as Targets for Cancer Therapy Krause DS, Van Etten RA N Engl J Med 2005;353(2): Krause DS, Van Etten RA N Engl J Med 2005;353(2):

Progress in Cancer Therapy Following Developments in Biopharma

YOUR CANCER TREATMENT: WHAT TO EXPECT FROM THE LATEST ADVANCEMENTS MIRIAM J. ATKINS, M.D.

EGFR exon 20 insertion mutations

Defining Epidermal Growth Factor Receptor exon 20 mutant sensitivity to tyrosine kinase inhibition Danny Rayes.

Samsung Genome Institute Samsung Medical Center

Frances A Shepherd, MD, Rafael Rosell, MD Journal of Thoracic Oncology

Integrated genomic and proteomic analysis identifies PTEN loss and AKT/MTOR as drivers of resistance to MEK inhibitors in NSCLC cells Dianren Xia1, Lauren.

Schema for a human microbiome study

Silvestri Gerard A. , MD, FCCP, Rivera M. Patricia , MD, FCCP CHEST

Defining Epidermal Growth Factor Receptor exon 20 mutant sensitivity to tyrosine kinase inhibition Danny Rayes.

Cetuximab Drugbank ID : DB00002

Figure 1. Resistance mechanism against first generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). (A) Mutations in the EGFR.

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth

Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR- Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients.

Inhibitor of MAP kinase activation blocks colon cancer growth

c-Kit as a Novel Potential Therapeutic Target in Colorectal Cancer

The PI3K/Akt signalling and its activation in cancer

Nat. Rev. Clin. Oncol. doi: /nrclinonc

The hallmarks of adenovirus infection

Schematic diagram of antibody drug conjugate

Latest Advances in Chemotherapeutic, Targeted, and Immune Approaches in the Treatment of Metastatic Melanoma Darshil J. Shah, MD, MPH, Roxana S. Dronca,

Figure 1 A schematic representation of the HER2 signalling pathway

Nat. Rev. Urol. doi: /nrurol

(A) An overview of the JAK/STAT signalling pathway.

Molecular approaches to HER2 targeted therapy

Model of the function of TBX2 in RMS.

Figure 2 from Sancho et al.

The cancer stem cell concept in cancer progression and metastasis

Figure 1 from B Zhu British Journal of Cancer (2015) 112, ; doi: /bjc

Sequencing of targeted therapies in HER2-positive metastatic breast cancer Figure 2 from Singh et al. British Journal of Cancer (2014) 111,

Figure 5 The mechanism underlying epithelial-to-mesenchymal

RESEARCH IN MOLECULAR THERAPI

A. Craig Lockhart, Mace L. Rothenberg, Jordan D. Berlin

Figure 1 from M Holderfield

Molecular features of the colon during homeostasis and carcinogenesis

Figure 1 from T Schenk et al.

HDACs class I, II, IV mutations in human cancer

Vascular Endothelial Growth Factor and Epidermal Growth Factor Signaling Pathways as Therapeutic Targets for Colorectal Cancer Thomas Winder, Heinz–Josef.

In melanoma tumours expressing the BRAFV600E oncogene RAF inhibitor treatment decreases ERK activation resulting in tumour regression and increased survival.

Erratum Journal of Thoracic Oncology

Mitochondrial priming model

Yan Feng, MD, Praveena S. Thiagarajan, PhD, Patrick C. Ma, MD

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

Spectrum of cellular processes regulated by AXL activity

The F-box protein Fbxw7 is required for maintenance of normal stem cells. Figure 1 from S Takeishi British Journal of Cancer (2014) 111, ; doi: /bjc

Molecular Characterization of Acquired Resistance to the BRAF Inhibitor Dabrafenib in a Patient with BRAF-Mutant Non–Small-Cell Lung Cancer Charles M.

Target antigens for ADCs in solid tumours

Macrophage differentiation and their role in tumourigenesis

Model of EphA/ephrin-A expression in GBM.

Tyrosine kinase inhibitors

The Current Role of Whole Brain Radiation Therapy in Non–Small Cell Lung Cancer Patients Gokoulakrichenane Loganadane, MD, Lizza Hendriks, MD, PhD, Cécile.

Presentation transcript:

Advanced Cancer Topics Journal Review 4/16/2009 AD

The Epidermal Growth Factor Receptor (EGFR) is a therapeutic target in many cancers In head and neck, colorectal, non-small cell lung, and other cancers, overexpression of EGFR can contribute to tumorigenesis. Therapeutic targeting of EGFR includes monoclonal antibodies that block ligand binding to the receptors and small-molecule tyrosine kinase inhibitors.

Cituximab (Erbitux) is a EGFR monocolonal antibody which inhibits ligand binding Preclinical Trials Indentified multiple mechanisms for Cituximab inhibition of tumor growth: (1)Inhibition of cell cycle progression; (2) inhibition of survival pathways; (3) inhibition of tumor cell motility and invasion; (4) inhibition of angiogenesis; and (5) Interruption of EGFR-activated survival and proliferation signaling by cytotoxic drugs or radiation

There are no good predictive markers for positive clinical response to Cituximab therapy The average treatment cost of cetuximab is about $61279 per patient The incremental cost per quality adjusted life-year gained is ~$57,608 Predictive tests would allow patients and physicians to make more informed care decision British Journal of Cancer (2007) 96, 206–212

Figure 1: Differential sensitivity of colon cancer cell lines to cetuximab treatment

Figure 2: Cell cycle analysis of cetuximab- sensitive and cetuximab-resistant colon cancer cell lines.

Figure 3: Basal EGFR mRNA and protein expression does not correlate with cetuximab response

Figure 3: Basal EGFR copy number does not correlate with cetuximab response

Figure 4: EGF selectively stimulates cell growth in cetuximab-sensitive cell lines

Figure 5: PIK3CA/PTEN mutation status predicts response to cetuximab in vitro

Conclusions This study confirms retrospective clinical reports sugguesting that cetuximab therapy should not be limited only to patients with EGFR-overexpressing tumors Identification of a potential predictive therapeutic marker (PTEN null) for Cituximab response –This is expected (a.k.a. Not that novel) because PTEN has previously been characterized downstream of EGFR and its loss is known to play a role in tumorigenesis These studies need further validation in vivo and correlations of PTEN mutational status to clinical outcomes data